Prosecution Insights
Last updated: November 11, 2026
Application No. 18/287,136

A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF

Final Rejection §103
Filed
Oct 16, 2023
Priority
Apr 17, 2021 — EU 21169034.2 +1 more
Examiner
BERRY, LAYLA D
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Studiengesellschaft Kohle gGmbH
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
963 granted / 1459 resolved
+6.0% vs TC avg
Moderate +9% lift
Without
With
+9.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
50 currently pending
Career history
1508
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
34.1%
-5.9% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1459 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . CONTINUING DATA This application is a 371 of PCT/EP2022/059801 04/12/2022 FOREIGN APPLICATIONS EP 21169034.2 04/17/2021 This office action is in response to Applicant’s amendment submitted August 10, 2026. Claims 1-10 are pending. The rejection of claims 8-10 under 35 U.S.C. 112(b) is withdrawn in view of Applicant’s amendment to include active method steps. The rejection of claim(s) 1-10 under 35 U.S.C. 102(a) as being anticipated by Jia is withdrawn. Applicant’s argument is persuasive. The examiner regrets the error. The following rejection of record is maintained. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-5 and 7-10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Unemoto (EP0382206A1, 1990, cited on IDS) in view of Ritter (EP3650446A1, 2020, cited on IDS), Liu (J. Phys. Org. Chem. 2001; 14: 81-89, cited on IDS) and Yus (Tetrahedron 59 (2003) 2083-2092). Unemoto teaches the following compound in Example 15: PNG media_image1.png 144 274 media_image1.png Greyscale The compound is used for introducing a perfluoroalkyl group into an organic compound (claim 9). Organic compounds into which the perfluoroalkyl group can be introduced include aromatic compounds (page 7, lines 44-46) or compounds containing C=O groups (Table 2). The compound is prepared as in Examples 4, 8, and 15: PNG media_image2.png 210 487 media_image2.png Greyscale PNG media_image3.png 215 449 media_image3.png Greyscale PNG media_image4.png 211 674 media_image4.png Greyscale Unemoto’s compound contains an oxygen and a sulfur atom, not two sulfur atoms as in the current claims. Liu teaches the following thianthrenium triflates for reacting with hydrocarbon nucleophiles (page 82 and Table 1): PNG media_image5.png 230 360 media_image5.png Greyscale Compound 3a was prepared by reaction of Th with methyl formate and triflic acid (page 82, right column). Ritter teaches the following compound for direct C-H functionalization (see abstract): PNG media_image6.png 179 187 media_image6.png Greyscale The resulting compound was then used to transfer the aromatic group to a methyl group (page 45) or an aromatic group (page 46). In one example, the triflate salt was converted to the PF6- salt [0106]. It would have been obvious to one of ordinary skill in the art at the time the application was filed to replace the oxygen in Unemoto’s compound with a sulfur in order to obtain a compound useful for transferring a trifluoromethyl group to an organic compound. Simple substitution of S for O would have resulted in the claimed invention, and the results would have been predictable because both Unemoto’s compound and the thianthrene compounds taught by Ritter or Liu are used for C-H functionalization. The skilled artisan would have prepared the thianthrene analog as Unemoto’s compound was prepared, using a thioether analog of the ether starting material. The thioether starting material was known at the art before the application was filed, as illustrated by Yus on page 2084 (compound 14), so the skilled artisan would have had a reasonable expectation of success in preparing the compound. Alternatively, the skilled artisan would have prepared the compound using the same methods used for preparing Liu’s compounds, which would imply the use of trifluoromethyl formate instead of methyl formate. Response to Arguments Applicant argues that the cited references fail to demonstrate that the claimed compound is preparable and has utility. This argument is not persuasive because the rejection above states the skilled artisan would have prepared the compound with the expectation that it would be useful for transferring a trifluoromethyl group to an organic compound. The above rejection also explains one or more methods by which the compound could be prepared. The above rejection takes into account only what was disclosed by the references. Applicant argues that a substitution of S for O would not have been predictable because it would alter the oxidation potential, sulfonium cation stability, and reactivity profile. This argument has been considered but is not persuasive because the prior art teaches successful transfer of an alkyl group to an organic group in either case. MPEP 2144 states: The Board affirmed the rejection finding “there was a ‘reasonable expectation’ that the tri- and tetra-orthoester fuel compositions would have similar properties based on ‘close structural and chemical similarity’ between the tri- and tetra-orthoesters and the fact that both the prior art and Dillon use these compounds ‘as fuel additives’.” In this instance, the cited references teach compounds which are of close structural similarity and are used for the same purpose. MPEP 2144 also states that obviousness does not require absolute predictability, only a reasonable expectation of success. In this instance, there is a reasonable expectation of success based on the compounds’ close structural similarities and common utilities. Claim(s) 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Unemoto (EP0382206A1, 1990, cited on IDS) in view of Ritter (EP3650446A1, 2020, cited on IDS), Liu (J. Phys. Org. Chem. 2001; 14: 81-89, cited on IDS) and Wang (CCS Chem. 2010, 2, 1710-1717). Unemoto, Ritter, and Liu teach as set forth above, and Liu teaches preparing the thianthrenium compounds using alkyl formates. Liu does not teach preparing the thianthrenium compound using triflic acid anhydride as the trifluoromethyl group transfer agent. Wang teaches trifluoromethylation reagents on page 1710, including triflic acid anhydride. PNG media_image7.png 134 599 media_image7.png Greyscale It would have been obvious too one of ordinary skill in the art at the time the application was filed to prepare the claimed compounds as set forth in the rejection above, and to prepare the compound using triflic acid anhydride. Liu teaches the use of alkyl formates for preparing the compounds, which implies the use of trifluoromethyl formate. An alternative trifluoromethylation agent is triflic acid anhydride, as taught by Wang. Simple substitution of one trifluoromethylation agent for another would have resulted in the claimed invention, and the results would have been predictable because both agents are used for trifluoromethylation. Response to Arguments Applicant’s arguments are the same as those addressed above. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA D BERRY whose telephone number is (571)272-9572. The examiner can normally be reached 7:00-3:00 CST, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA D BERRY/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Oct 16, 2023
Application Filed
Feb 10, 2026
Non-Final Rejection mailed — §103
Aug 10, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103
Nov 09, 2026
Request for Continued Examination
Nov 10, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779771
CELLULOSE-BASED FILAMENTS, FILMS AND 3D OBJECTS AND METHODS OF MANUFACTURE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12781027
Molding Material
2y 7m to grant Granted Nov 03, 2026
Patent 12780862
Methyl Fructoside Polyether Amine, Preparation Method Therefor and Use Thereof
2y 5m to grant Granted Nov 03, 2026
Patent 12774298
AMORPHOUS FORM OF 5-BROMOPYRIDIN-3-YL 3-DEOXY-3-[4-(3,4,5-TRIFLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL]-1-THIO-ALPHA-D-GALACTOPYRANOSIDE
5y 4m to grant Granted Oct 27, 2026
Patent 12765551
ANTIMICROBIAL COMPOSITION COMPRISING A MODIFIED ALKYL GLYCOSIDE AND AN ALKANEDIOL
3y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
75%
With Interview (+9.1%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1459 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month